Xenograft Model Antitumor Assays
"Xenograft Model Antitumor Assays" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
| Descriptor ID |
D023041
|
| MeSH Number(s) |
E05.337.550.200.900 E05.624.850
|
| Concept/Terms |
Xenograft Model Antitumor Assays- Xenograft Model Antitumor Assays
- Tumor Xenograft Assay
- Xenograft Antitumor Assays
- Antitumor Assay, Xenograft
- Antitumor Assays, Xenograft
- Assay, Xenograft Antitumor
- Assays, Xenograft Antitumor
- Xenograft Antitumor Assay
- Antitumor Assays, Xenograft Model
|
Below are MeSH descriptors whose meaning is more general than "Xenograft Model Antitumor Assays".
Below are MeSH descriptors whose meaning is more specific than "Xenograft Model Antitumor Assays".
This graph shows the total number of publications written about "Xenograft Model Antitumor Assays" by people in this website by year, and whether "Xenograft Model Antitumor Assays" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 3 | 3 |
| 2003 | 0 | 5 | 5 |
| 2004 | 0 | 6 | 6 |
| 2005 | 1 | 5 | 6 |
| 2006 | 0 | 2 | 2 |
| 2007 | 1 | 6 | 7 |
| 2008 | 0 | 6 | 6 |
| 2009 | 1 | 5 | 6 |
| 2010 | 2 | 13 | 15 |
| 2011 | 1 | 8 | 9 |
| 2012 | 2 | 13 | 15 |
| 2013 | 0 | 16 | 16 |
| 2014 | 2 | 23 | 25 |
| 2015 | 0 | 32 | 32 |
| 2016 | 2 | 35 | 37 |
| 2017 | 3 | 25 | 28 |
| 2018 | 2 | 31 | 33 |
| 2019 | 1 | 32 | 33 |
| 2020 | 0 | 18 | 18 |
| 2021 | 0 | 21 | 21 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
| 2024 | 3 | 8 | 11 |
| 2025 | 0 | 11 | 11 |
To return to the timeline,
click here.
Below are the most recent publications written about "Xenograft Model Antitumor Assays" by people in Profiles.
-
Tuning CAR-T cells by targeting cancer-associated glycan in pancreatic cancer. Nat Commun. 2025 Dec 10; 16(1):11246.
-
FTO degrader impairs ribosome biogenesis and protein translation in acute myeloid leukemia. Sci Adv. 2025 Aug 15; 11(33):eadv7648.
-
Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth. Mol Cancer Ther. 2025 Aug 01; 24(8):1252-1264.
-
Secretion of a VEGF-Blocking scFv Enhances CAR T-cell Potency. Cancer Immunol Res. 2025 Aug 01; 13(8):1132-1144.
-
EZH2 inhibitor SHR2554 enhances the anti-tumor efficacy of HDAC inhibitor Chidamide through STAT1 in T-cell lymphoma. Cell Death Dis. 2025 Jul 14; 16(1):522.
-
PARP-1 as a novel target in endocrine-resistant breast cancer. J Exp Clin Cancer Res. 2025 Jun 16; 44(1):175.
-
IFN-?-resistant CD28 CAR T cells demonstrate increased survival, efficacy, and durability in multiple murine tumor models. Sci Transl Med. 2025 Jun 04; 17(801):eadp8166.
-
Dual inhibition of ATR and DNA-PKcs radiosensitizes ATM-mutant prostate cancer. Oncogene. 2025 Jun; 44(22):1746-1760.
-
Anti-PD1 prolongs the response of PI3K and farnesyl transferase inhibition in HRAS- and PIK3CA-mutant head and neck cancers. Neoplasia. 2025 05; 63:101157.
-
DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemia. Blood. 2025 Mar 13; 145(11):1182-1194.